Sternon J, Appelboom T
CUMG-ULB, Hôpital Erasme, U.L.B.
Rev Med Brux. 1998 Feb;19(1):29-32.
NSAID's are currently medications widely prescribed. Meloxicam is a new oxicam which has a low COX-2/COX-1 ratio, i.e. it has an inhibitory effect focused on the inflammatory proteins (COX-2) with relative saving of the homeostatic proteins (COX-1). This molecule has been studied in three rheumatic diseases, the acute flare-up of osteoarthritis, rheumatoïd arthritis, and ankylosing spondylitis. The results show that meloxicam is as effective as comparative NSAID's. A global analysis of the data from more than 5000 patients included in clinical trials showed that gastro-intestinal tolerance of meloxicam was better than that of comparative NSAID'S. Nevertheless, the clinical translation of the anti-COX-2 selectivity concept is currently debated.
非甾体抗炎药（NSAID）目前是广泛处方的药物。美洛昔康是一种新型的昔康类药物，其COX - 2/COX - 1比率较低，也就是说它对炎症蛋白（COX - 2）具有抑制作用，同时相对保留了维持体内平衡的蛋白（COX - 1）。该分子已在三种风湿性疾病中进行了研究，即骨关节炎急性发作、类风湿关节炎和强直性脊柱炎。结果表明，美洛昔康与对照非甾体抗炎药的效果相当。对纳入临床试验的5000多名患者的数据进行的综合分析表明，美洛昔康的胃肠道耐受性优于对照非甾体抗炎药。然而，抗COX - 2选择性概念的临床转化目前仍存在争议。
